Neurocrine Biosciences
NBIX
213 hedge funds and large institutions have $3.47B invested in Neurocrine Biosciences in 2016 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 86 increasing their positions, 74 reducing their positions, and 37 closing their positions.
125% more funds holding in top 10
Funds holding in top 10: 4 → 9 (+5)
40% more call options, than puts
Call options by funds: $22.7M | Put options by funds: $16.2M
16% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 74
5% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 37
3% less funds holding
Funds holding: 219 → 213 (-6)
26% less capital invested
Capital invested by funds: $4.71B → $3.47B (-$1.24B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$48.9M |
| 2 |
HM
HealthCor Management
New York
|
+$28.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$26.9M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$25.3M |
| 5 |
Goldman Sachs
New York
|
+$22.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$33.1M |
| 2 |
PC
PointState Capital
New York
|
-$29.7M |
| 3 |
RIM
RS Investment Management
San Francisco,
California
|
-$23.8M |
| 4 |
CCI
Columbus Circle Investors
|
-$18.2M |
| 5 |
VAM
Visium Asset Management
New York
|
-$13.4M |
NBIX Hedge Fund Activity: Q1 2016 in Review
213 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2016, worth a combined $3.47B — down 26% from $4.71B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of NBIX and 35 opened new positions — a net loss of 2 holders — while 74 trimmed existing stakes and 86 added.
The largest buyer was Sectoral Asset Management, adding an estimated $48.9M. The largest seller was Lord, Abbett & Co, exiting entirely with an estimated $33.1M sold.
- 213 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2016, down from 219 in Q4 2015.
- Funds reported $3.47B of Neurocrine Biosciences stock for Q1 2016, down 26% quarter-over-quarter.
- 35 funds opened new Neurocrine Biosciences positions in Q1 2016 and 37 closed out, a net change of -2 holders.
- The largest Neurocrine Biosciences buyer in Q1 2016 was Sectoral Asset Management, an estimated $48.9M added.
- The largest Neurocrine Biosciences seller in Q1 2016 was Lord, Abbett & Co, an estimated $33.1M sold.
Based on aggregated 13F filings for Q1 2016.